» Articles » PMID: 12377967

Comparative Detection of Lymph Node Micrometastases of Stage II Colorectal Cancer by Reverse Transcriptase Polymerase Chain Reaction and Immunohistochemistry

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2002 Oct 16
PMID 12377967
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Inconsistent conclusions have been drawn about the clinical significance of micrometastases in lymph nodes (LNs) of node-negative colorectal cancer (CRC) patients. We performed a comparative study of detection of micrometastases using immunohistochemistry (IHC) by anti-cytokeratin antibody and carcinoembryonic antigen (CEA)-specific reverse-transcriptase polymerase chain reaction (RT-PCR) in the same patients, in an attempt to move closer to their clinical application.

Patients And Methods: Sixty-four CRC patients, with RNA of good quality available from paraffin-embedded LN specimens, were selected from 84 stage II patients who underwent curative surgery between 1988 and 1996. We investigated associations between the presence of micrometastases by each method and prognosis.

Results: Micrometastases were detected in 19 (29.6%) of 64 patients by RT-PCR and in 35 (54.7%) of 64 patients by IHC. By RT-PCR analysis, patients exhibiting a positive band for CEA mRNA had a significantly worse prognosis than those who were RT-PCR-negative, with respect to both disease-free and overall survival (P =.027 and.015, respectively). By IHC analysis, the presence of micrometastasis did not predict patient outcome in terms of either disease-free or overall survival. Infiltrating pattern of tumor growth characteristic was significantly associated with shorter disease-free survival among various clinical or pathologic factors. By multivariate Cox regression analysis, micrometastasis detected by RT-PCR and the Crohn's-like lymphoid reaction were both independent prognostic factors.

Conclusion: Micrometastases detected by RT-PCR, but not IHC, may be of clinical value in identifying patients who may be at high risk for recurrence of CRC and who are therefore likely to benefit from systemic adjuvant therapy.

Citing Articles

Essential updates 2020/2021: Advancing precision medicine for comprehensive rectal cancer treatment.

Takemasa I, Hamabe A, Miyo M, Akizuki E, Okuya K Ann Gastroenterol Surg. 2023; 7(2):198-215.

PMID: 36998300 PMC: 10043777. DOI: 10.1002/ags3.12646.


A nomogram model based on MRI and radiomic features developed and validated for the evaluation of lymph node metastasis in patients with rectal cancer.

Su Y, Zhao H, Liu P, Zhang L, Jiao Y, Xu P Abdom Radiol (NY). 2022; 47(12):4103-4114.

PMID: 36102961 DOI: 10.1007/s00261-022-03672-5.


Micrometastasis in lymph nodes of colorectal cancer.

Yamamoto H Ann Gastroenterol Surg. 2022; 6(4):466-473.

PMID: 35847437 PMC: 9271024. DOI: 10.1002/ags3.12576.


Prognostic Impact of Carcinoembryonic Antigen Levels in Rectal Cancer Patients Who Had Received Neoadjuvant Chemoradiotherapy.

Joo J, Lim S, Oh B Ann Coloproctol. 2021; 37(3):179-185.

PMID: 33971705 PMC: 8273711. DOI: 10.3393/ac.2020.11.27.


Histopathologic risk stratification of stage IIB colorectal cancer.

Komori K, Kinoshita T, Oshiro T, Ito S, Abe T, Senda Y Surg Today. 2017; 47(8):934-939.

PMID: 28039532 DOI: 10.1007/s00595-016-1456-8.